Browse > Article
http://dx.doi.org/10.24304/kjcp.2019.29.2.133

Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study  

Kim, Jiyoon (College of Pharmacy, Gachon University)
Lee, Kyunggyu (College of Pharmacy, Gachon University)
Kim, Junyoung (College of Pharmacy, Gachon University)
Lee, Jung-Min (Regional Pharmacovigilance Center, Korean Pharmaceutical Association)
Kim, Na-Young (Regional Pharmacovigilance Center, Korean Pharmaceutical Association)
Lee, Mo-Se (Regional Pharmacovigilance Center, Korean Pharmaceutical Association)
Ji, Eunhee (College of Pharmacy, Gachon University)
Publication Information
Korean Journal of Clinical Pharmacy / v.29, no.2, 2019 , pp. 133-137 More about this Journal
Abstract
Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have experienced visual field defect, which recovered after drug discontinuation. She had never experienced this symptom before, and several studies have reported an association between use of statins and visual disorders such as blurred vision, diplopia, and cataract. Blockage of cholesterol accumulation, oxidative stress, or myopathy is expected to be a cause of this symptom. Naranjo scale, Korean causality assessment algorithm (Ver.2), and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were the three tools used to determine causality between the visual disorder and atorvastatin. The results represent 'probable', 'certain', and 'probable/likely' causality, respectively. Our results, in combination with a review of literature, indicate that ocular adverse effects are highly likely related to atorvastatin.
Keywords
Atorvastatin; visual field defect; adverse drug reaction; causality assessment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kawashiri MA, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008;83(5):731-9.   DOI
2 Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005;31(5):572-80.   DOI
3 Dirks AJ and Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006;291(6):C1208-12.   DOI
4 Urso ML, Clarkson PM, Hittel D, et al. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005;25(12):2560-6.   DOI
5 Liantonio A, Giannuzzi V, Cippone V, et al. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/ mitochondria $Ca^{2+}$-release system. J Pharmacol Exp Ther 2007;321(2):626-34.   DOI
6 ClinCalc.com DrugStats Database. Atorvastatin, Drug Usage Statistics, United States, 2006-2016. Available from http://clincalc.com/DrugStats/Drugs/Atorvastatin. Accessed March 10, 2019.
7 Mizranita V and Pratisto EH. Statin-associated ocular disorders: the FDA and ADRAC data. Int J Clin Pharm 2015;37(5):844-50.   DOI
8 Korean Index of Medical Specialties (KIMS). Atorvastatin. Available from http://www.kimsonline.co.kr/drugcenter/generic/geninfo/GATR0. Accessed March 10, 2019.
9 Lee SH, Park S, Kang SM, et al. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia. J Cardiovasc Pharmacol Ther 2012;17(1):65-71.   DOI
10 Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107(19):2409-15.   DOI
11 Bahrami B, Rajak S, Selva D. Orbital myositis secondary to statin therapy. Med J Aust 2015;203(9):365.   DOI
12 Zelenka PS. Lens lipids. Curr Eye Res 1984;3(11):1337-59.   DOI
13 Fraunfelder FW and Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology 2008;115(12):2282-5.   DOI
14 Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci 2012;89(8):1165-71.   DOI
15 Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol 1996;40(4):320-37.   DOI
16 Spurgeon D. Antibiotic use with cholesterol lowering drugs may increase risk of cataracts. BMJ 2002;325(7374):1194.   DOI
17 Satoh K, Yamato A, Nakai T, et al. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol 1995;116(2):1894-8.   DOI
18 Kanski JJ and Bowling B. Clinical Ophthalmology: A Sytematic Approach, 7th ed. Philadelphia, PA: Elsevier 2011:269-310.
19 Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf 2009;4(3):209-28.   DOI
20 Satoh K and Ichihara K. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts. Eur J Pharmacol 1995;292(3-4):271-5.   DOI
21 Willis RA, Folkers K, Tucker JL, et al. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990;87(22):8928-30.   DOI
22 Littarru GP and Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007;7(suppl):S168-74.   DOI